If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. If you see this, it …
There's been a notable change in appetite for Sylvamo Corporation (NYSE:SLVM) shares in the week since its first-quarter report, with the stock down 11% to US$52.64. Revenues of US$821m were in line with forecasts, although statutory earnings per share (EPS) came in below expectations …
First Citizens BancShares (NASDAQ:FCNC.A) First Quarter 2025 Results Key Financial Results Revenue: US$2.14b (down 10.0% from 1Q 2024). Net income: US$468.0m (down 35% from 1Q 2024). Profit margin: 22% (down from 30% in 1Q 2024). EPS: US$34.48 (down from US$49.27 in 1Q 2024). We've …
Enbridge Inc. ENB reported first-quarter 2025 adjusted earnings per share (EPS) of 72 cents, which beat the Zacks Consensus Estimate of 68 cents. The bottom line increased from the year-ago quarter’s level of 68 cents. (Find the latest EPS estimates and surprises on Zacks …
Global advertising conglomerate Interpublic Group (NYSE:IPG) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 8.5% year on year to $2 billion. Its non-GAAP profit of $0.33 per share was 27.2% above analysts’ consensus estimates. Is now the time to buy …
BankUnited (NYSE:BKU) First Quarter 2025 Results Key Financial Results Revenue: US$240.3m (up 6.1% from 1Q 2024). Net income: US$57.7m (up 22% from 1Q 2024). Profit margin: 24% (up from 21% in 1Q 2024). The increase in margin was driven by higher revenue. EPS: US$0.78 …
Telecommunications and media company Comcast (NASDAQ:CMCSA) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $29.89 billion. Its non-GAAP profit of $1.09 per share was 10.1% above analysts’ consensus estimates. Is now the time to buy CMCSA? …
The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.
This story was originally published on Marketing Dive. To receive daily news and insights, subscribe to our free daily Marketing Dive newsletter. Dive Brief: CMOs expect their budgets to stay flat in 2025, though macroeconomic uncertainty could lead to in-year cuts, according to Gartner’s …
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Additional CX-2051 …